Apellis Pharmaceuticals, Inc. (APLS) News

Apellis Pharmaceuticals, Inc. (APLS): $42.50

0.25 (-0.58%)

POWR Rating

Component Grades

Momentum

D

Stability

D

Sentiment

Quality

D

Filter APLS News Items

APLS News Results

Date Symbol Company Title Start End Change POWR Rating
Loading, please wait...

APLS News Highlights

  • APLS's 30 day story count now stands at 10.
  • Over the past 23 days, the trend for APLS's stories per day has been choppy and unclear. It has oscillated between 1 and 4.
  • DEC, DRUG and EYE are the most mentioned tickers in articles about APLS.

Latest APLS News From Around the Web

Below are the latest news stories about APELLIS PHARMACEUTICALS INC that investors may wish to consider to help them evaluate APLS as an investment opportunity.

Apellis Pharmaceuticals to Host a Fireside Chat at the Goldman Sachs Healthcare C-Suite Unscripted Conference

WALTHAM, Mass., Dec. 28, 2023 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) today announced that the company will host a fireside chat at the Goldman Sachs Healthcare C-Suite Unscripted Conference on Thursday, January 4, 2023, at 2:25 p.m. ET. The event will be available via a live webcast from the “Events and Presentations” page of the “Investors and Media” section of the company’s website. A replay of the webcast will be available for approximately 90 days following the even

Yahoo | December 28, 2023

Wall Street Analysts Just Trimmed Price Targets for These 10 Stocks

In this article, we will discuss the 10 stocks whose price targets were recently trimmed by analysts. If you want to see more such stocks on the list, go directly to Wall Street Analysts Just Trimmed Price Targets for These 5 Stocks. In the latest market developments on December 18, Asian stocks experienced a notable decline, […]

Yahoo | December 18, 2023

Apellis (APLS) Falls on Europe Update for Pegcetacoplan in GA

The CHMP may adopt a negative opinion on Apellis' (APLS) intravitreal pegcetacoplan for the treatment of geographic atrophy secondary to age-related macular degeneration in the EU. Stock declines.

Yahoo | December 15, 2023

Apellis Crashes 17% As It Stares Down A Likely European Rejection

Apellis said Thursday it expects European regulators to reject its eye disease drug, Syfovre. APLS stock tumbled below its 200-day line.

Yahoo | December 14, 2023

UPDATE 1-Apellis says EU regulator panel may not back its eye disease drug

Apellis Pharmaceuticals said on Thursday the European drug regulator's advisory panel may decline to back an authorization for its drug to treat a chronic eye disease, sending its shares down more than 14% in premarket trading. The company said it was informed on Wednesday that the panel may vote against the drug, a form of pegcetacoplan directly injected in the back of the eye, at the next meeting on Jan. 22-25.

Yahoo | December 14, 2023

Apellis Provides Update on Ongoing Regulatory Review of Pegcetacoplan for GA in the European Union

Conference call today at 8:30 a.m. ETWALTHAM, Mass., Dec. 14, 2023 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) announced today an update on the ongoing review of its marketing authorization application (MAA) for intravitreal pegcetacoplan for the treatment of geographic atrophy (GA) secondary to age-related macular degeneration (AMD) by the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA). Following the oral explanation meeting on

Yahoo | December 14, 2023

Apellis eye drug likely to be rejected in Europe, company says

According to Apellis executives, reviewers in Europe are skeptical of the benefits of its geographic atrophy medicine, Syfovre, and appear poised to recommend against approval at a meeting next month.

Yahoo | December 14, 2023

EMPAVELI® (pegcetacoplan) Provided Long-Term Control of PNH in New Data Presented at ASH Annual Meeting

Rapid improvements in key markers of disease were sustained for up to three years across all adults with PNHMajority of patients remained transfusion free over the long termZero cases of meningococcal infection observed over three years in this analysisData shared during an oral presentation WALTHAM, Mass., Dec. 11, 2023 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) and Sobi today presented post hoc data that reinforce the long-term efficacy and safety of EMPAVELI® (pegcetacop

Yahoo | December 11, 2023

Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

WALTHAM Mass., Dec. 06, 2023 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS), today announced that the company approved the grant of equity awards to 4 new employees with a grant date of December 1, 2023, as equity inducement awards outside of the company's 2017 Stock Incentive Plan (but under the terms of the 2020 Inducement Stock Incentive Plan) and material to the employees’ acceptance of employment with the company. The equity awards were approved in accordance with Nasdaq L

Yahoo | December 6, 2023

Nike assumed at Buy, 'near-term challenges well understood': 4 big analyst picks

Here is your Pro Recap of the biggest analyst picks you may have missed since yesterday: Buy assumptions at Nike and Block, and upgrades at Crown Castle and Apellis Pharmaceuticals. Goldman Sachs assumed coverage on Nike (NYSE:NKE) with a Buy rating and a price target of $139.00 (from $136 prior), as reported in real-time on InvestingPro. The analysts expect an upturn in Nike's earnings growth.

Yahoo | December 5, 2023


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!